39 results on '"Ferretti G."'
Search Results
2. C8 - Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis
3. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
4. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe dʼOncologie de langue française (GOLF)
5. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
6. The other side of p53
7. Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number
8. What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial?
9. Does low-molecular-weight heparin influence cancer-related mortality?
10. Molecular stool testing for the early detection of colorectal cancer: swan song for p53?
11. Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
12. Chemotherapy-induced amenorrhea in early breast cancer
13. Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?
14. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
15. Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
16. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer
17. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter
18. Zoledronic acid-associated thrombotic thrombocytopenic purpura
19. Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin
20. THE RADIOMETABOLIC TREATMENT OF BONE METASTASIS: OUR EXPERIENCE WITH 153 SM
21. TWO PARALLEL STUDIES COMPARING TRASTUZUMAB (T) PLUS VINORELBINE (V) IN HER2-POSITIVE WITH VINORELBINE ALONE IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PATIENTS (PTS)
22. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
23. Bone scan had no role in the staging of 765 consecutive operable T1-2N0-1 breast cancer patients without skeletal symptoms
24. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
25. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
26. Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial
27. Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
28. Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis
29. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
30. Frequency, patterns and prognostic impact of distant metastases in a large mono-institutional series of malignant pleural mesothelioma (MPM): Not necessarily bad news
31. Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial
32. 1488P - Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial
33. 340P - Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
34. Dose-finding study on a continuous dose of oral vinorelbine (VNR) in heavily pre-treated metastatic breast cancer (MBC) patients (pts)
35. Phase I of weekly nab-paclitaxel in combination with weekly liposomal encapsulated doxorubicin as first-line treatment for HER2 negative metastatic breast cancer patients: preliminary results
36. 1336P - ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
37. 1515P - Frequency, patterns and prognostic impact of distant metastases in a large mono-institutional series of malignant pleural mesothelioma (MPM): Not necessarily bad news
38. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma
39. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.